This trial is evaluating whether Treatment will improve 1 primary outcome in patients with Mitral Valve Insufficiency. Measurement will happen over the course of 0-48 hours.
This trial requires 12 total participants across 2 different treatment groups
This trial involves 2 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase < 1 and are in the first stage of evaluation with people.
Patients from any state can participate in this trial, so long as they are able to attend all treatment sessions.
There is not cost involved in participating in this trial, so insurance won't be necessary.